Fertility benefits company Progyny (NASDAQ: PGNY) will be reporting results this Wednesday after the bell. Here’s what to expect.
Progyny beat analysts’ revenue expectations last quarter, reporting revenues of $350.5 million, up 5.3% year on year. It was a slower quarter for the company, with EBITDA guidance for next quarter missing analysts’ expectations significantly and full-year revenue guidance slightly missing analysts’ expectations.
Is Progyny a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Progyny’s revenue to grow 8.8% year on year, in line with the 9.3% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Progyny rarely misses Wall Street’s revenue estimates.
Looking at Progyny’s peers in the health insurance providers segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Elevance Health posted flat year-on-year revenue, beating analysts’ expectations by 3.1%, and UnitedHealth reported flat revenue, topping estimates by 1.2%. Elevance Health traded up 1.2% following the results while UnitedHealth was also up 4.5%.
Read our full analysis of Elevance Health’s results here and UnitedHealth’s results here.
There has been positive sentiment among investors in the health insurance providers segment, with share prices up 2.4% on average over the last month. Progyny is up 14.6% during the same time and is heading into earnings with an average analyst price target of $34.42 (compared to the current share price of $29.63).
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
